NCT04496167已完成2 期
A Phase 2, Randomized, Double Blind, Placebo Controlled Study of the Safety and Efficacy of EN3835 for the Treatment of Adhesive Capsulitis of the Shoulder
Endo Pharmaceuticals38 个研究点 分布在 1 个国家目标入组 198 人开始时间: 2020年7月29日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 198
- 试验地点
- 38
- 主要终点
- Change From Baseline in the Adapted American Shoulder and Elbow Surgeons Shoulder Assessment Form (ASES) Composite Score for the Affected Shoulder at Day 95
研究概览
简要总结
This study will evaluate the safety and efficacy of EN3835 for the treatment of adhesive capsulitis of the shoulder (frozen shoulder).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have idiopathic unilateral adhesive capsulitis (also known as frozen shoulder).
- •Have unaffected range of motion in the contralateral shoulder as determined by the investigator.
- •Be willing to undergo x-ray and magnetic resonance imaging (MRI) of both affected and unaffected shoulder.
- •Agree to participate in supervised, in-office physical therapy sessions and to complete home exercises at designated time points during the study.
- •Agree to avoid general lifting and carrying during the study as instructed.
- •Be able to read, understand, and independently complete participant reported outcome instruments in English.
- •If female, be of non-childbearing potential (history of hysterectomy, bilateraloophorectomy, bilateral tubal ligation, or postmenopausal with no history of menstrual flow in the 12 months prior to the Screening Visit); or, if of childbearing potential, be non-pregnant, non-lactating and agree to use effective contraception when with a male partner for the duration of the study (and for 28 days after any active treatment period for participant who early terminate). Acceptable forms of contraception include hormonal measures (oral contraceptive pills, contraceptive patch, contraceptive ring, and injections), intrauterine devices, double barrier method (condom plus diaphragm, condom or diaphragm plus spermicidal gel or foam), surgical sterilization of the male partner, and abstinence.
- •If male with reproductive potential, agree to use effective contraception (abstinence, surgical sterilization [vasectomy], or condom with spermicide) with a female partner of child-bearing potential for the duration of the study (and for 28 days after any active treatment period for participant who early terminate).
- •Be willing and able to cooperate with the requirements of the study.
- •Be adequately informed and understand the nature and risks of the study and be able to provide consent .
排除标准
- •Has a known allergy to collagenase or any other excipient of EN3835 or any other procedural medication (including local anesthetics).
- •Has received treatment for adhesive capsulitis (in the timeframes outlined below) or is planning to receive any treatment (other than study treatment) for adhesive capsulitis at any time during the study in the affected shoulder, including but not limited to:
- •Physical therapy or acupuncture within 2 weeks before the first injection of study treatment.
- •Intra-articular or intrabursal injection(s) of lidocaine, suprascapular nerve blocks, or electroanalgesic and/or thermoanalgesic modalities within 1 month before the Screening Visit.
- •Intra-articular or intrabursal injection(s) of corticosteroids within 8 weeks before the Screening Visit.
- •Intra-articular or intrabursal injection(s) of sodium hyaluronate and/or glenohumeral distension arthrography within 3 months before the Screening Visit.
- •Manipulation under anaesthesia at any time prior to the study.
- •Surgery (including arthroscopic or open capsular release, capsulectomy, or capsulotomy) at any time prior to the study.
- •Has any abnormalities/conditions in the affected shoulder that would be potentially confounding as determined by the central MRI review committee grading criteria.
- •Has a prosthesis or replacement of right or left shoulder, elbow, wrist, and/or hand.
- •Has systemic conditions (malignancy, hypertension, diabetes, thyroid disease, thrombosis, physical impairment, infection, significant medical condition) that restricts study participation.
- •Has any contraindications for MRI (implant containing metal, internal metallic object, permanent cosmetics/make-up/tattoos, claustrophobia, anemia, uncontrolled hypertension, epilepsy, asthma, sickle cell disease) as determined by the technologist, the radiologist, and/or investigator performing the imaging, with exemption of the area to be treated/reviewed.
- •Has a known coagulation disorder or is taking any medications that would increase the risk of bleeding (except <150 milligrams of aspirin daily), 7 days prior to first injection and for the duration of the study.
- •Has received oral or parenteral steroids for any reason within 3 weeks before the Screening Visit.
- •Has, at any time, received collagenase for the treatment of adhesive capsulitis (including participant who received treatment in Study AUX-CC-870 or AUX-CC-871).
- •Has received treatment with an investigational product within 30 days (or 5 half lives, whichever is longer) of the screening visit.
- •Has received collagenase treatments (for example, Santyl® ointment and/or XIAFLEX/XIAPEX®) for any other indication within 30 days prior to study treatment administration, or is planning to be treated with collagenase (other than study treatment) at any time during the study.
- •Has donated blood within 30 days prior to the Screening Visit or has plans to donate blood during the study.
- •Has a corrected QT interval (QTc) of ≥ 450 milliseconds (ms) for male participant or ≥470 ms for female participant on the screening electrocardiogram (ECG).
- •Is from a vulnerable population, as defined by the US Code of Federal Regulations (CFR) Title 45, Part 46, Section 46.111(b) and other local and national regulations, including but not limited to, employees (temporary, part-time, full-time, etc) or a family member of the research staff conducting the study, or of the sponsor, or of the contract research organization, or of the Institutional Review Board (IRB)/Independent Ethics Committee (IEC).
- •Has concurrent diseases that might interfere with the conduct of the study, confound the interpretation of the study results, or endanger the participant's well-being, (for example, evidence of any significant hematological, endocrine, cardiovascular, respiratory, neurological, renal, hepatic, or gastrointestinal disease). If there is a history of such disease but the condition has been stable for more than 5 year(s) and is judged by the investigator not to interfere with the participant's participation in the study, the participant may be included, with the documented approval of the Medical Monitor.
- •Has any other condition(s) that, in the investigator's opinion, might indicate the participant to be unsuitable for the study.
研究组 & 干预措施
EN3835
Experimental
EN3835 up to 1.74 mg
干预措施: EN3835 (Drug)
Placebo
Placebo Comparator
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Change From Baseline in the Adapted American Shoulder and Elbow Surgeons Shoulder Assessment Form (ASES) Composite Score for the Affected Shoulder at Day 95
时间窗: Baseline, Day 95
Adapted ASES is a self-administered participant reported outcome measure, divided into 2 sections: pain and function. Pain subscale is a single item, 11-point numeric rating scale, ranging from 0 (no pain at all) to 10 (worst pain), calculated as 10 - pain raw score and multiplying by 5, score ranging from 0 (worst pain) to 50 (no pain). Function subscale consists of 10 activities, 4-point ordinal scale about their ability to do the activity with the affected arm, ranging from 0 (unable to do) to 3 (not difficult), calculated by multiplying total score for 10 items by 5 and then dividing it by 3, score range of 0 (no function) to 50 (full function). Adapted ASES composite score is the sum of the pain subscale score (50% of the composite score) and function subscale score (50% of the composite score), score range of 0 (worst pain) to 100 (least pain). Positive change from Baseline score means an improvement in pain and/or shoulder function.
次要结局
- Change From Baseline in PROM for Internal Rotation in the Affected Shoulder(Baseline, Days 22, 43, 64, and 95)
- Change From Baseline in PROM for Internal Rotation in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline(Baseline, Days 22, 43, 64, and 95)
- Change From Baseline in PROM for External Rotation in the Affected Shoulder(Baseline, Days 22, 43, 64, and 95)
- Change From Baseline in PROM for Abduction in the Affected Shoulder(Baseline, Days 22, 43, 64, and 95)
- Change From Baseline in PROM for Shoulder Extension in the Affected Shoulder(Baseline, Days 22, 43, 64, and 95)
- Change From Baseline in PROM for Forward Flexion in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline(Baseline, Days 22, 43, 64, and 95)
- Change From Baseline in Passive Range of Motion (PROM) for Forward Flexion in the Affected Shoulder(Baseline, Days 22, 43, 64, and 95)
- Change From Baseline in PROM for External Rotation in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline(Baseline, Days 22, 43, 64, and 95)
- Change From Baseline in AROM for Abduction in the Affected Shoulder(Baseline, Days 22, 43, 64, and 95)
- Change From Baseline in AROM for Forward Flexion in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline(Baseline, Days 22, 43, 64, and 95)
- Change From Baseline in AROM for Abduction in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline(Baseline, Days 22, 43, 64, and 95)
- Change From Baseline in the Pain Upon Movement (PUM) Scale Score for the Affected Shoulder(Baseline, Days 64 and 95)
- Change From Baseline in PROM for Abduction in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline(Baseline, Days 22, 43, 64, and 95)
- Change From Baseline in Active Range of Motion (AROM) for Forward Flexion in the Affected Shoulder(Baseline, Days 22, 43, 64, and 95)
- Change From Baseline in the Adapted ASES Function Subscale Score(Baseline, Day 22, 43, 64, and 95)
- Change From Baseline in Patient-reported Global Severity of Adhesive Capsulitis Scale(Baseline, Day 22, 43, 64, and 95)
- Patient-reported Change in Severity of Adhesive Capsulitis Scale(Days 22, 43, 64 and 95)
- Number of Responders Assessed With Investigator Assessment of Improvement(Days 64 and 95)
- Change From Baseline in PROM for Shoulder Extension in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline(Baseline, Days 22, 43, 64, and 95)
- Change From Baseline in AROM for Shoulder Extension in the Affected Shoulder(Baseline, Days 22, 43, 64, and 95)
- Change From Baseline in AROM for External Rotation in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline(Baseline, Days 22, 43, 64, and 95)
- Change From Baseline in AROM for Internal Rotation in the Affected Shoulder(Baseline, Days 22, 43, 64, and 95)
- Change From Baseline in AROM for Internal Rotation in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline(Baseline, Days 22, 43, 64, and 95)
- Change From Baseline in the Adapted ASES Pain Subscale Score(Baseline, Day 22, 43, 64, and 95)
- Number of Responders Assessed by the Subject Satisfaction With Treatment Assessment(Days 64 and 95)
- Change From Baseline in AROM for External Rotation in the Affected Shoulder(Baseline, Days 22, 43, 64, and 95)
- Change From Baseline in AROM for Shoulder Extension in the Affected Shoulder Compared to the Contralateral (Unaffected) Shoulder at Baseline(Baseline, Days 22, 43, 64, and 95)
- Change From Baseline in the Adapted ASES Composite Score(Baseline, Day 22, 43, and 64)
- Number of Participants Positive for Anti-AUX-I and Anti-AUX-II Antibodies(Day 95)
- Number of Participants Positive for Neutralizing Antibodies(Day 95)
研究者
研究点 (38)
Loading locations...
相似试验
已完成
3 期
Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)Plantar FibromatosisLedderhose DiseaseNCT06151197Endo USA Inc., a Keenova Therapeutics Company436
已完成
2 期
Safety and Effectiveness of EN3835 in the Treatment of EFP in WomenEdematous Fibrosclerotic PanniculopathyCelluliteNCT03329989Endo Pharmaceuticals158
已完成
2 期
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)Edematous Fibrosclerotic PanniculopathyCelluliteNCT02724644Endo Pharmaceuticals375
已完成
2 期
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)Edematous Fibrosclerotic PanniculopathyCelluliteNCT02942160Endo Pharmaceuticals259
终止
2 期
A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain SyndromeInterstitial CystitisBladder Pain SyndromeNCT05740007Ironwood Pharmaceuticals, Inc.98